We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

77 hedge funds and large institutions have $586M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 4

351% more capital invested

Capital invested by funds: $130M → $586M (+$456M)

244% more call options, than puts

Call options by funds: $592K | Put options by funds: $172K

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

88% more funds holding

Funds holding: 41 → 77 (+36)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
77
Holders Change
+36
Holders Change %
+87.8%
% of All Funds
1.12%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
40
Increased
17
Reduced
8
Closed
4
Calls
$592K
Puts
$172K
Net Calls
+$420K
Net Calls Change
+$420K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$17.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.52M
3
William Blair & Company
William Blair & Company
Illinois
+$4.83M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.62M
5
APM
Avidity Partners Management
Texas
+$3.49M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$3.5M
2
SFM
Sphera Funds Management
Israel
-$1.31M
3
GTC
Ghost Tree Capital
New York
-$633K
4
UOC
UBS O'Connor
Illinois
-$299K
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$171K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$105M +$983K +202,364 +2%
APM
2
Avidity Partners Management
Texas
$62.5M +$3.49M +718,478 +12%
DM
3
Deerfield Management
New York
$61.5M +$17.4M +3,578,000 +127%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$51.1M +$5.52M +1,135,446 +27%
JJ
5
Johnson & Johnson
New Jersey
$35.3M – – –
O
6
OrbiMed
New York
$30M – – –
Canada Pension Plan Investment Board
7
Canada Pension Plan Investment Board
Ontario, Canada
$30M – – –
ASP
8
Adams Street Partners
Illinois
$28.3M – – –
PA
9
Perceptive Advisors
New York
$26.4M – – –
TGA
10
TPG GP A
Texas
$24.5M – – –
PBPIA
11
Pivotal bioVenture Partners Investment Advisor
California
$15M – – –
SFM
12
Sphera Funds Management
Israel
$10.4M -$1.31M -268,619 -20%
AG
13
Artal Group
Luxembourg
$9.66M -$3.5M -719,500 -42%
William Blair & Company
14
William Blair & Company
Illinois
$9.55M +$4.83M +993,855 New
Wellington Management Group
15
Wellington Management Group
Massachusetts
$7.15M +$3.62M +744,474 New
1832 Asset Management
16
1832 Asset Management
Ontario, Canada
$7.06M – – –
EHI
17
Eagle Health Investments
Connecticut
$5.57M – – –
Millennium Management
18
Millennium Management
New York
$5.56M -$19.6K -4,027 -0.7%
IC
19
Ikarian Capital
Texas
$4.81M +$2.43M +500,000 New
BlackRock
20
BlackRock
New York
$4.03M +$2M +411,553 +4,987%
Morgan Stanley
21
Morgan Stanley
New York
$3.98M +$1.21M +248,326 +150%
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$3.84M +$1.94M +400,000 New
Marshall Wace
23
Marshall Wace
United Kingdom
$3.06M +$1.55M +318,440 New
FAM
24
Fred Alger Management
New York
$3M +$1.52M +311,974 New
Jennison Associates
25
Jennison Associates
New York
$2.89M +$1.46M +301,020 New
1
2 3 4

FUSN Hedge Fund Activity: Q4 2023 in Review

77 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q4 2023, worth a combined $586M — up 351% from $130M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new FUSN positions and 4 closed out — a net gain of 36 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was Deerfield Management, adding an estimated $17.4M. The largest seller was Artal Group, cutting an estimated $3.5M.

  • 77 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q4 2023, up from 41 in Q3 2023.
  • Funds reported $586M of Fusion Pharmaceuticals Inc. Common Shares stock for Q4 2023, up 351% quarter-over-quarter.
  • 40 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q4 2023 and 4 closed out, a net change of +36 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q4 2023 was Deerfield Management, an estimated $17.4M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q4 2023 was Artal Group, an estimated $3.5M sold.

Based on aggregated 13F filings for Q4 2023.